Trifluridine–Tipiracil with and without Bevacizumab in Colorectal Cancer
This U.S.-based real-world observational study found that FTD-TPI+bev was associated with longer rwOS compared with FTD-TPI in patients with mCRC. These findings align with the results of the SUNLIGHT clinical trial. (Funded by Taiho Oncology, Inc. and others.).
Authors
- Ruizhi Zhao
- Christopher Cann (ORCID: https://orcid.org/0000-0002-6960-6460)
- Tehseen Salimi
- Y. Wang
- Maliha Nusrat
- Kathryn Penney
- Nadeem Khan
Institutions
- Fox Chase Cancer Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Concert Pharmaceuticals (United States) (US)
- Taiho Oncology (United States) (US)
Publication Details
- Journal
- NEJM Evidence
- Published
- 2026-02-24
- DOI
- https://doi.org/10.1056/evidoa2500120
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 24.20